top
Search terms
Results 1 - 5 of 5 - ordered by :
Ehjournal

[...]in coronary artery disease, not only lipids matter, but inflammation is about to become a major therapeutic target.4 Inflammation involves cellular and humoral factors.5,6 Thus, knowledge of ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/03/2016 Item size : 161003 bytes
Ehjournal

[...]in coronary artery disease, not only lipids matter, but inflammation is about to become a major therapeutic target.4 Inflammation involves cellular and humoral factors.5,6 Thus, knowledge of ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/03/2016 Item size : 188455 bytes
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015 Item size : 220026 bytes
Ehjournal

[...]congenital heart disease, either in the young or in adults, often leads to pump failure and death.6 This issue begins with a Current Opinion article entitled Should extensive myocardial ...

European Heart Journal, Lüscher, Thomas F.

Date : 07/09/2015 Item size : 4411 bytes